Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran
Malak Rizk, Şükrü Tüzmen Molecular Biology and Genetics Program, Department of Biological Sciences, Faculty of Arts and Sciences, Eastern Mediterranean University (EMU), Famagusta, North Cyprus, Turkey Abstract: RNA interference (RNAi) is a naturally existing endo...
Main Authors: | Rizk M, Tüzmen S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-11-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/update-on-the-clinical-utility-of-an-rna-interference-based-treatment--peer-reviewed-article-PGPM |
Similar Items
-
Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
by: Luca Gentile, et al.
Published: (2021-04-01) -
Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects
by: Massimo Russo, et al.
Published: (2020-12-01) -
Hereditary transthyretin amyloidosis
by: T. A. Adyan, et al.
Published: (2020-01-01) -
The role of non-coding genetic variants on transthyretin gene transcription in transthyretin amyloidosis
by: Boldbaatar, Batbold
Published: (2021) -
Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity
by: Ana Frangolho, et al.
Published: (2020-12-01)